Angeles Alvarez Secord, MD

Angeles A. Secord, MD, MHSc, discusses safety findings from the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive ovarian cancer.

Angeles A. Secord, MD, MHSc, discusses the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive, FRα-high ovarian cancer.

Angeles A. Secord, MD, discusses the design of the phase 3b OReO trial in ovarian cancer.

Angeles A. Secord, MD, discusses the individual therapeutic preferences and treatment considerations for patients with platinum-sensitive ovarian cancer.

Angeles A. Secord, MD, discusses treating patients with platinum-sensitive ovarian cancer.

Angeles Alvarez Secord, MD, discusses key takeaways from clinical trials that have evaluated frontline maintenance strategies in patients with advanced ovarian cancer.

Angeles Alvarez Secord, MD, discusses a presentation from the 2020 SGO Winter Meeting that focused on assistance with the financial burden associated with PARP inhibitors in patients with ovarian cancer.

Angeles Alvarez Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses the role of PARP inhibitors in ovarian cancer based on their current indications in the treatment landscape.

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the growing potential for personalized treatment in ovarian cancer.

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the management of patients with sarcoma.

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the use of biomarkers to guide treatment decisions in patients with ovarian cancer.

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses determining the management strategy for patients with ovarian cancer.

Angeles Alvarez Secord, MD, gynecologic cancers specialist, Duke Cancer Center, discusses the importance of understanding patient preferences regarding treatment regimens.